Delivering Pluripotent Stems Cells Primed to Differentiate

On the Road to 50 States, Benjamin Fryer, a senior executive at Pluristxy, talks to Nigel about pluripotent stem cells and how the company speeds up the R&D process by delivering 'ready to differentiate' cells. 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Pluristyx

Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx provides seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-to-Use (RTU™) and Ready-To-Differentiate (RTD™) Pluripotent Stem Cells at a commercial scale. In doing so, Pluristyx effectively decouples the hassles of expansion and banking from differentiation and product development, allowing early-stage companies to focus precious resources on therapeutic application rather than manufacturing hurdles, with the ultimate goal of advancing promising laboratory discoveries into patients.

Q: